ABSTRACT
Myoscint consists of a Fab fragment of a monoclonal antibody against human cardiac myosin, conjugated to a linker-chelator for coupling with the radioisotope Indium 111 (In 111). The murine monoclonal antibody is produced by standard hybridoma technology using B cells taken from the spleen of mice immunized with human cardiac myosin fused to a myeloma cell line. The purified antibody undergoes enzymatic digestion with papain to generate Fab fragments, which are then conjugated to the linker-chelator, diethylenetriaminepentaacetic acid. Purification involves several chromatographic steps and other procedures to ensure viral safety. The final product is presented in a kit containing a solution of imciromab pentetate (active), as well as a sodium phosphate buffer, sodium chloride, and maltose as excipients, and a second solution containing a sodium citrate buffer. The latter is mixed with the antibody solution before coupling with the radioisotope In 111, which is not supplied.
